Indivior Pharmaceuticals Inc (INDV) Stock
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About Indivior Pharmaceuticals Inc
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
Indivior Pharmaceuticals Inc (INDV) stock trades at $40.48 with a market capitalization of $5.05B. The stock is valued at a price-to-earnings (P/E) ratio of 20.16, price-to-book of -35.28, price-to-sales of 3.92. Over the past 52 weeks the stock has ranged between $16.69 and $42.81, and currently trades 5.4% below its 52-week high.
On profitability, Indivior Pharmaceuticals Inc generates a return on equity (ROE) of -142.01%, return on capital employed of 102.87%, an operating margin of 33.31%, a net profit margin of 19.44%.
Official website: www.indivior.com